{"denoms":[{"counts":[{"groupId":"BG000","value":"24"}],"units":"Participants"}],"groups":[{"description":"Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nGemcitabine Hydrochloride: Given IV\n\nDocetaxel: Given IV","id":"BG000","title":"Treatment (Gemcitabine Hydrochloride, Docetaxel)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"<50 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"60-69 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"70-79 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":">79 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligible and treated patients"}